Group 1 - The core viewpoint of the article highlights the recent research conducted by Shanghai Chengrui Investment on a listed company, Puluo Pharmaceutical, which is planning a third share buyback plan by 2025 and is currently processing related procedures [1] - Puluo Pharmaceutical's cephalosporin product prices have decreased by approximately 15%, while penicillin product prices remain stable, and the price of florfenicol is expected to rebound in the third quarter [1] - The company's CDMO business is projected to grow by 20%-30% with a gross margin of 40%-45%, while the raw material drug business faces pressure with a slight decline in sales volume, controlling gross margin contribution to within 10% [1] - New products such as ferrous fumarate chewable tablets are expected to drive growth, alongside the release of older products like levetiracetam and succinic acid metoprolol [1] - The company has completed the enrollment for the third phase of the clinical trial for the weight loss project of semaglutide, with 40% enrollment progress for the diabetes indication [1] - Puluo Pharmaceutical has established a digital innovation team to utilize AI for optimizing fermentation processes, significantly enhancing fermentation efficacy [1] Group 2 - Shanghai Chengrui Investment, established in May 2010, has a registered capital of 110 million and has been recognized for its stable development and diverse client base, including banks, private banks, and various institutional investors [2] - The company has a professional investment research team of 33 members, with backgrounds from prestigious universities both domestically and internationally [2] - Chengrui Investment has received multiple awards and recognitions over the years, including being listed among the top private equity funds in China and winning various industry awards for its performance [2]